UBS raised its target price for Kelun Botai Bio (06990.HK) to HK$678 from HK$667
and reiterated a Buy rating. UBS said H1 product revenue was 657 mln yuan, above
its expectation. The bank lifted EPS forecasts for 2026–28 to 2.41, 2.09 and
8.29 yuan per share and now projects 2026 product revenue of 14.3 bln yuan.